Physician profile
Grace Ruidera
NPI 1407886492
$5,314.61
in general payments reported to CMS, 2019-2025
33 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $480 · 2021: $584 · 2022: $864 · 2023: $980 · 2024: $1,100 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,111 · Education: $58.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,110.70 |
| Education | $58.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $876.87 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $725.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $548.13 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $542.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $393.11 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $283.51 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $263.25 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.13 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.63 | 2019-2024 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.76 | 2019-2022 | |
| Exact Sciences Corporation | $128.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $126.50 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Allergan, INC. | $112.83 | 2019-2020 | |
| Amgen INC. | $102.96 | 2019-2025 | Otezla, Repatha, Tepezza |
| Dexcom, INC. | $98.09 | 2021-2023 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $95.73 | 2019-2023 | |
| Advanced Respiratory, INC | $61.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $47.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.04 | 2024 | Trintellix |
| Mylan Specialty L.P. | $31.01 | 2024 | Yupelri |
| Baxter Healthcare | $29.56 | 2022 | |
| Dermira, INC. | $28.99 | 2020 | |
| Lundbeck LLC | $26.00 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $24.65 | 2023 | |
| Radius Health, INC. | $23.36 | 2024 | Tymlos |
| Horizon Therapeutics Plc | $23.32 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $18.36 | 2019 | |
| Eisai INC. | $17.99 | 2021 | |
| Genentech USA, INC. | $16.74 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.75 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $15.30 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.86 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Ruidera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.